PDPN and glioblastoma: In a study, an anti-PDPN monoclonal antibody, humLpMab-23, was humanized, and a defucosylated form, humLpMab-23-f, was produced to enhance its effectiveness in targeting PDPN-overexpressed cells, particularly in GBM.